GSK376501

GlaxoSmithKline · Phase 1 active Small molecule

GSK376501 is a small molecule drug developed by GlaxoSmithKline, currently in Phase 1 clinical trials. It has been studied for its effects on CYP450 activity and metabolism in healthy and overweight subjects, with no FDA label yet. The drug's safety and efficacy are under investigation, and it has not been approved for any indications.

At a glance

Generic name	GSK376501
Also known as	placebo
Sponsor	GlaxoSmithKline
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GSK376501 CI brief — competitive landscape report
GSK376501 updates RSS · CI watch RSS
GlaxoSmithKline portfolio CI